Palvella Therapeutics (NASDAQ:PVLA) Rating Increased to Strong-Buy at Stephens

Palvella Therapeutics (NASDAQ:PVLA) was upgraded by Stephens to a “strong-buy” rating in a research note issued to investors on Tuesday,Zacks.com reports.

A number of other analysts also recently weighed in on PVLA. Truist Financial set a $210.00 price target on shares of Palvella Therapeutics in a report on Tuesday, February 24th. BTIG Research upped their price objective on shares of Palvella Therapeutics from $192.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Wall Street Zen cut shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Mizuho upped their price target on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Finally, Stifel Nicolaus set a $250.00 price target on shares of Palvella Therapeutics in a report on Tuesday, February 24th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $199.53.

Palvella Therapeutics Trading Up 3.0%

Shares of Palvella Therapeutics stock opened at $125.79 on Tuesday. The company has a 50 day moving average of $125.41 and a 200-day moving average of $103.44. Palvella Therapeutics has a 1-year low of $20.20 and a 1-year high of $151.18. The company has a market cap of $1.80 billion, a PE ratio of -30.17 and a beta of -0.13.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.30). Research analysts forecast that Palvella Therapeutics will post -5.28 earnings per share for the current year.

Insider Activity at Palvella Therapeutics

In related news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total value of $507,592.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director George M. Jenkins acquired 4,000 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The stock was bought at an average price of $125.00 per share, with a total value of $500,000.00. Following the completion of the acquisition, the director directly owned 187,171 shares of the company’s stock, valued at $23,396,375. This trade represents a 2.18% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 20.50% of the stock is currently owned by company insiders.

Institutional Trading of Palvella Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. KBC Group NV acquired a new stake in Palvella Therapeutics in the first quarter valued at $28,000. Group One Trading LLC increased its holdings in Palvella Therapeutics by 151.5% in the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after purchasing an additional 200 shares during the period. Archer Investment Corp acquired a new stake in Palvella Therapeutics in the third quarter valued at $28,000. Russell Investments Group Ltd. acquired a new stake in Palvella Therapeutics in the third quarter valued at $36,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in Palvella Therapeutics in the fourth quarter valued at $167,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.